Clinical Trial Detail

NCT ID NCT03884829
Title A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Cyclacel Pharmaceuticals, Inc.
Indications

leukemia

myelodysplastic syndrome

Therapies

CYC140

Age Groups: adult senior

No variant requirements are available.